Young Tae Kim
Family Medicine · Duluth, GANPI 1902391923
Payments from drug & device makers
Across 857 payments — averaging $22.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Biolase, Inc.$2K
- Amgen$2K
- AstraZeneca$936
- Gilead$924
- Amarin Pharma, Inc.$896
- plus $9K from 45 others
What the payments were for
- Food & beverage$18,79399%
- Education$1581%
- Gifts$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,976 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 352 | $286,013 |
| ProliaDenosumab | 149 | $257,073 |
| FarxigaDapagliflozin Propanediol | 167 | $211,305 |
| CreonLipase/Protease/Amylase | 78 | $133,804 |
| OzempicSemaglutide | 79 | $114,625 |
| ZenpepLipase/Protease/Amylase | 31 | $69,020 |
| TradjentaLinagliptin | 55 | $59,595 |
| JardianceEmpagliflozin | 42 | $49,152 |
| LinzessLinaclotide | 39 | $49,029 |
| JanuviaSitagliptin Phosphate | 30 | $40,422 |
| RybelsusSemaglutide | 13 | $38,018 |
| GemtesaVibegron | 33 | $35,483 |
| EliquisApixaban | 31 | $34,590 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 25 | $24,343 |
| Repatha SureclickEvolocumab | 23 | $24,263 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenProlia | $2,310 | $257,073149 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $936 | $221,304184 claims |
| AbbVieCreon, Linzess, Vraylar, Namzaric | $2,960 | $215,173150 claims |
| Novo NordiskOzempic, Rybelsus | $445 | $152,64392 claims |
| Boehringer IngelheimTradjenta, Jardiance | $85 | $108,74797 claims |
| Aimmune Therapeutics, Inc.Zenpep | $350 | $69,02031 claims |
| MerckJanuvia | $219 | $40,42230 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $364 | $35,48333 claims |
| PfizerEliquis | $810 | $34,59031 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $142 | $31,55668 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $665 | $24,34325 claims |
| Astellas Pharma US IncMyrbetriq | $337 | $14,23721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Duluth
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.